Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
The purpose of this study is to evaluate the safety of 2.0 mg/kg and 4.0 mg/kg sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium in cardiac patients
Epistemonikos ID: 7c2ac439b4ad070f6246cdf11e70b7a9b24fcd62
First added on: May 04, 2024